ArticlePloS one2015
Copolymer-1 promotes neurogenesis and improves functional recovery after acute ischemic stroke in rats.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation.Cells · 2022Pooled it
- The Immunologic Function of the Choroid Plexus: A Gateway to Immunomodulatory Therapy in Injury Models of the Central Nervous System.International journal of molecular sciences · 2026Review
- Immunomodulation induced by central nervous system-related peptides as a therapeutic strategy for neurodegenerative disorders.Pharmacology research & perspectives · 2021Review
- Long Non-coding RNAs as Promising Therapeutic Approach in Ischemic Stroke: a Comprehensive Review.Molecular neurobiology · 2021Review
- Thinking outside the Ischemia Box: Advancements in the Use of Multiple Sclerosis Drugs in Ischemic Stroke.Journal of clinical medicine · 2021Review
- Synergic Neuroprotection BetweenFrontiers in pharmacology · 2021Article
- Immunization with neural-derived peptides increases neurogenesis in rats with chronic spinal cord injury.CNS neuroscience & therapeutics · 2020Article
- B cells migrate into remote brain areas and support neurogenesis and functional recovery after focal stroke in mice.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Blood-Brain Barrier Damage in Ischemic Stroke and Its Regulation by Endothelial Mechanotransduction.Frontiers in physiology · 2020Review
- Autoimmunity in acute ischemic stroke and the role of blood-brain barrier: the dark side or the light one?Frontiers of medicine · 2019Review
- Use of a combination strategy to improve neuroprotection and neuroregeneration in a rat model of acute spinal cord injury.Neural regeneration research · 2019Article
- Release of interleukin-10 and neurotrophic factors in the choroid plexus: possible inductors of neurogenesis following copolymer-1 immunization after cerebral ischemia.Neural regeneration research · 2018Article
- Pharmacological approaches promoting stem cell-based therapy following ischemic stroke insults.Acta pharmacologica Sinica · 2018Review
- Potentially Common Therapeutic Targets for Multiple Sclerosis and Ischemic Stroke.Frontiers in physiology · 2018Article
- Immunotherapy of experimental and human stroke with agents approved for multiple sclerosis: a systematic review.Therapeutic advances in neurological disorders · 2018Review
- Article
- Immunization with neural derived peptides plus scar removal induces a permissive microenvironment, and improves locomotor recovery after chronic spinal cord injury.BMC neuroscience · 2017Article
- Immunization with Cop-1 promotes neuroprotection and neurogenesis after ischemic stroke.Neural regeneration research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke triggers a systemic inflammatory response that exacerbates the initial injury. Immunizing with peptides derived from CNS proteins can stimulate protective autoimmunity (PA). The most renowned of these peptides is copolymer-1 (Cop-1) also known as glatiramer acetate. This peptide has been approved for use in the treatment of multiple sclerosis. Cop-1-specific T cells cross the blood-brain barrier and secrete neurotrophins and anti-inflammatory cytokines that could stimulate proliferation of neural precursor cells and recruit them to the injury site; making it an ideal therapy for acute ischemic stroke. The aim of this work was to evaluate the effect of Cop-1 on neurogenesis and neurological recovery during the acute phase (7 days) and the chronic phase of stroke (60 days) in a rat model of transient middle cerebral artery occlusion (tMCAo). BDNF and NT-3 were quantified and infarct volumes were measured. We demonstrated that Cop-1 improves neurological deficit, enhances neurogenesis (at 7 and 60 days) in the SVZ, SGZ, and cerebral cortex through an increase in NT-3 production. It also decreased infarct volume even at the chronic phase of tMCAo. The present manuscript fortifies the support for the use of Cop-1 in acute ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.